[1] Dragan P D, Ivan S B, Goran D Z, et al.The Role of Systemic Oxidative Status in Coronary Arterial and Peripheral Venous Blood of Patients with Unstable Angina Pectoris[J] . Life, 2023, 13(7): 1537.
[2] 王悦,王志强,刘倍倍,等.不稳定型心绞痛患者经皮冠状动脉介入术后长期应用小剂量替格瑞洛的抗凝疗效分析[J] .心肺血管病杂志,2021,40(1):6-11.
[3] 常国栋,陈英伟.替格瑞洛在氯吡格雷抵抗急性心肌梗死患者PCI术后抗血小板治疗中的应用效果[J] .中国循证心血管医学杂志,2018,10(4):466-468.
[4] 董艳丽,董淑娟.替格瑞洛片联合阿司匹林片用于经皮冠状动脉介入术的急性ST段抬高型心肌梗死患者的临床研究[J] .中国临床药理学杂志,2019,35(7):614-616.
[5] Sami S, Willerson J T.Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 1)[J] . Texas Heart Institute Journal, 2010, 37(2): 141.
[6] Gragnano F, Moscarella E, Calabro P, et al.Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry[J] . Internal and Emergency Medicine, 2021, 16: 379-387.
[7] Misumida N, Aoi S, Kim S M, et al.Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: systematic review and meta-analysis[J] . Cardiovascular Revascularization Medicine, 2018, 19(6): 689-694.
[8] Park D W, Kwon O, Jang J S, et al.Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial[J] . Circulation, 2019, 140(23): 1865-1877.
[9] 滕晓焕,赵兰蒂.增强型体外反搏在心脏康复中的应用[J] .安徽医药,2020,24(2):217-220.
[10] 罗建宇,王晓源,韦淑婧,等.主动脉内球囊反搏联合体外膜肺氧合在心源性休克患者中的应用[J] .内科,2020,15(4):440-442.
[11] 刘贞,赵佳佳,樊俊雅,等.增强型体外反搏对不稳定型心绞痛患者血管内皮舒张功能及血浆脂蛋白磷脂酶A2水平的影响[J] .实用医学杂志,2019,35(3):437-439.
[12] 张照,赵佳佳,樊俊雅,等.增强型体外反搏对冠状动脉慢血流患者血管内皮功能和左室舒张功能的影响[J] .中国心血管杂志,2019,24(2):148-151.
[13] 钱承嗣,蒋峻.注射用丹参多酚酸联合曲美他嗪治疗老年冠心病心绞痛患者疗效及对炎性因子、血管内皮损伤和血脂的影响[J] .中国老年学杂志,2021,41(21):4614-4617.
[14] 程修平,宫丽鸿,李楠,等.EECP联合中西医疗法治疗高血压的临床疗效及对ET、NO、AngⅡ的影响[J] .中国中医急症,2017,26(3):481-484. |
